(VIANEWS) – The Market ended the session with SEQUANA MEDICAL (SEQUA.BR) rising 9.35% to €2.69 on Wednesday, after two consecutive sessions in a row of losses. BEL 20 rose 0.17% to €3,511.22, after two successive sessions in a row of losses, on what was a somewhat positive trend trading session today.
SEQUANA MEDICAL’s last close was €2.46, 62.84% under its 52-week high of €6.62.
About SEQUANA MEDICAL
Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Earnings Per Share
As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.32.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -690.43%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 17.3%, now sitting on 842.41k for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SEQUANA MEDICAL’s stock is considered to be overbought (>=80).
Volatility
SEQUANA MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.13%, a negative 0.58%, and a positive 3.26%.
SEQUANA MEDICAL’s highest amplitude of average volatility was 2.30% (last week), 4.47% (last month), and 3.26% (last quarter).
More news about SEQUANA MEDICAL (SEQUA.BR).
